aGvHD prophylaxis consisted of CSA and MTX (n=197; 46.5%) or MMF (n=189; 44.6%); or other combinations (n=29); ex vivo CD34-enrichment (TCD) without additional GvHD prophylaxis (n=6), or no GvHD prophylaxis for other reasons (n=2). This evidence concerns the gene CD34 and graft versus host disease.